305PD Clinical profile of germ cell tumor of ovary - A single centreexperience

Abstract

Background Germ cell tumor of ovary (GCT) constitutes around 3% of all ovarian neoplasms. Methods Patients with newly diagnosed ovarian GCT who were being treated in our institute from July’ 2012 to June’2016 were included in this study. Mode of presentation, histology, treatment outcomes and toxicity of the treatment were recorded. Results Eighteen patients were treated during this time period withmedian age of 28 years (range 12 -51 years).Most common mode of presentation was pain abdomen (66%), followed by abdominal distension (22%). Yolk sac tumor (YST)was themost common histology in 11 patients (61%) and the stage at presentation was I in 11(61%), II in 1(0.5%), III in 4(22%) and IVin 2(11%). Two patients didn’t undergo surgery. All patients except two (stage IA dysgerminoma) were treated with chemotherapy (BEP in 13 and EP in 4).Four patients with YST had post treatment elevation of serumAlpha fetoprotein (AFP) level. Two of themhad slow resolution of AFP over time. Two patients had persistently elevated AFP levels for which salvage chemotherapy was given.One patient developed grade 4 neuropathy with slow resolution of AFP level and one was lost for follow upMost common toxicity was febrile neutropenia in 9 patients (50%). Two patients developed grade 4 neuropathy.After amedian followup of 17.7months (range 2.9-41.5months), median progression free survival (PFS) has not been reached and 3 year PFS is 86.7%. Conclusions Ovarian GCT is a highly curable malignancy with multimodalitytreatment including surgery and cytotoxic chemotherapy with acceptable toxicity. The challenges remain in limiting long-term treatment related toxicity. Legal entity responsible for the study N/A Funding N/A Disclosure All authors have declared no conflicts of interest.